A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Nocturia
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan; Serenity Pharmaceuticals Corporation
  • Most Recent Events

    • 05 Oct 2017 Results from pooled post-hoc analysis of this and another phase III trial presented in an Avadel Pharmaceuticals media release.
    • 05 Oct 2017 According to an Avadel Pharmaceuticals media release, pooled post-hoc analysis of this and another phase III trial (see CT profile 700235061) will be presented at the Pelvic Floor Disorders (PFD) Week 2017, the American Urogynecologic Society's annual scientific meeting.
    • 20 May 2017 Results of a pooled analysis of the NCT01357356 and NCT01900704 assessing efficacy/safety of SER120 1.5 mcg and 0.75 mcg, in nocturia patients (pts) more than or equal to 65 yrs of age, presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top